Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

RPRX stock hub

Royalty Pharma plc has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

RPRXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

29.2B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

RPRX

In the news

Latest news · RPRX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E9.7

P25 12.3P50 18.4P75 33.1

Trailing P/E26.8

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC5.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All RPRX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

228

Groups with data

Currency

USD

Showing 228 of 228 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001802768
Company name	Royalty Pharma plc
Country	United States
Country code	US
Cusip	G7709Q104
Employees	100
Employees Change	1%
Employees Change Percent	1.01
Enterprise value	$37.6B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2020-06-16
Isin	GB00BMVP7Y09
Last refreshed	2026-05-10
Market cap	$29.2B
Market cap category	Large-Cap
Price	$50.79
Price currency	USD
Rev Per Employee	24,411,930x
Sector	Healthcare
Sic	2834
Symbol	RPRX
Website	https://www.royaltypharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.83%
EV Earnings	45.44x
EV Sales Forward	10.95x
EV/EBIT	22.64x
EV/Sales	15.39x
Forward P/E	9.73x
P/B ratio	3.36x
P/E ratio	26.76x
P/S ratio	11.98x
PE Ratio3 Y	23.63x
PE Ratio5 Y	45.22x
PEG ratio	0.91x
PS Forward	8.52x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	67.98%
Gross margin	114.99%
Gross Profit	$2.8B
Gross Profit Growth	25.2%
Gross Profit Growth Q	19.07%
Gross Profit Growth3 Y	22.67%
Gross Profit Growth5 Y	9.79%
Net Income	$826.9M
Net Income Growth	-24.31%
Net Income Growth Q	23.77%
Net Income Growth Quarters	2%
Net Income Growth Years	0%
Net Income Growth3 Y	35.58%
Net Income Growth5 Y	10.9%
Pretax Margin	55.68%
Profit Margin	33.87%
Profit Per Employee	$8.3M
Profitable Years	9
Roa5y	4.83
Roe5y	11.64
ROIC	5.75

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	58.82%
Cagr3y	16.2%
Cagr5y	6.86%
Div CAGR3	5.27%
EPS Growth	-22.57
EPS Growth Q	-2.83
EPS Growth Quarters	2
EPS Growth Years	0
EPS Growth3 Y	36.12
EPS Growth5 Y	9.38
OCF Growth	-3.28%
OCF Growth Q	20.45%
OCF Growth3 Y	-1.31%
OCF Growth5 Y	4.56%
Revenue Growth	7.83x
Revenue Growth Q	11.04x
Revenue Growth Quarters	5x
Revenue Growth Years	1x
Revenue Growth3 Y	1.15x
Revenue Growth5 Y	2.15x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	$637.5M
Debt	$9B
Debt Equity	$0.92
Equity	$9.7B
Interest Coverage	4.93
Net Cash	$-8.3B
Net Cash By Market Cap	$-28.49
Net Debt Equity	$0.86
Tangible Book Value	$5.6B
Tangible Book Value Per Share	$12.95
WACC	5.61

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	5.1%
Dividend Growth	5.81%
Dividend Growth Years	6%
Dividend per share	$0.94
Dividend Years	7
Dividend Yield	1.85%
Ex Div Date	2026-05-15
Last Dividend	$0.24
Payout Frequency	Quarterly
Payout Ratio	47.94%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	58.77%
200-day SMA	40.91
3Y total return	56.91%
50-day SMA	47.85
50-day SMA vs 200-day SMA	50over200
5Y total return	39.34%
All Time High	56.5
All Time High Change	-10.11%
All Time High Date	2020-06-18
All Time Low	24.05
All Time Low Change	111.19%
All Time Low Date	2024-12-19
ATR	1.04
Beta	0.4
Beta1y	0.49
Beta2y	0.19
Ch YTD	31.44
High	51.17
High52	51.65
High52 Date	2026-05-06
High52ch	-1.67%
Low	50.5
Low52	32.15
Low52 Date	2025-05-23
Low52ch	57.98%
Ma50ch	6.15%
Premarket Change Percent	0.84
Premarket Price	$50.62
Price vs 200-day SMA	24.14%
RSI	64.46
RSI Monthly	76.64
RSI Weekly	80.83
Sharpe ratio	2.04x
Sortino ratio	3.41
Total Return	6.95%
Tr YTD	32.13
Tr1m	8.36%
Tr1w	2.67%
Tr3m	14.35%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	6
Analyst Count Top	3
Analyst Price Target Top	$62
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$1.19
Earnings EPS Estimate Growth	12.26
Earnings Revenue Estimate	877,543,592x
Earnings Revenue Estimate Growth	54.5x
Operating Income	$1.7B
Operating Income Growth	-12.68
Operating Income Growth Q	18.5
Operating Income Growth3 Y	11.97
Operating Income Growth5 Y	1.66
Operating margin	67.98
Price target	$55.17
Price Target Change	$8.62
Price Target Change Top	$22.07

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	435,893,986%
Float Percent	75.7%
Net Borrowing	954,475,000
Shares Insiders	1.36%
Shares Institutions	82.59%
Shares Out	575,832,204
Shares Qo Q	0.18%
Shares Yo Y	-5.1%
Short Float	2.76%
Short Ratio	3.77
Short Shares	2.09

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	3,176,781.75x
Bv Per Share	15.11
Ch1m	8.36
Ch1w	2.67
Ch1y	55.08
Ch3m	13.75
Ch3y	44.7
Ch5y	23.97
Ch6m	31.72
Change	1.18%
Change From Open	0.02
Close	50.2
Days Gap	1.16
Depreciation Amortization	3,852,000
Dollar Volume	110,873,198.7
Earnings Date	2026-05-06
Earnings Time	bmo
EBIT	$1.7B
EPS	$1.9
F Score	4
Financing CF	-517,973,000
Fiscal Year End	December
Founded	1,996
Graham Number	25.40345
Graham Upside	-49.98
Investing CF	-2,596,180,000
Ipr	81.39
Iprfo	15.43
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-11
Lynch Fair Value	$20.68
Lynch Upside	-59.28
Ma150	42.45
Ma150ch	19.65%
Ma20	49.63
Ma20ch	2.34%
Net CF	-502,330,000
Next Earnings Date	2026-08-05
Open	50.78
Optionable	Yes
P OCF Ratio	11.2
Payment Date	2026-06-10
Position In Range	43.28
Post Close	50.79
Postmarket Change Percent	0.88
Postmarket Price	$51.24
Pre Close	50.2
Price Date	2026-05-08
Ptbv Ratio	5.27
Relative Volume	0.69x
Revenue	2,441,193,000x
SBC By Revenue	11.88x
Share Based Comp	289,894,000
Tr6m	33.14%
Us State	New York
Volume	2,182,973

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

RPRX dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+1.9%

$0.94 annual per share

Payout ratio

+47.9%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

n/a

6 consecutive years of growth

Total shareholder yield

+7.0%

Next ex-dividend date: 2026-05-15

Performance

RPRX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns RPRX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+82.6%

Float: +75.7% of shares outstanding

Insider ownership

+1.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

RPRX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

64.5

Neutral momentum band

Price vs 200-day MA

+24.1%

50/200-day relationship not available

Beta (5Y)

0.40

Less volatile than the market

Sharpe ratio

2.04

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About RPRX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current RPRX stock rating?

Royalty Pharma plc is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full RPRX analysis?

The full report lives at /stocks/RPRX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for RPRX?

The latest report frames RPRX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the RPRX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.